Iron chelation for amelioration of liver ischemia-reperfusion injury

Hemoglobin. 2010 Jun;34(3):265-77. doi: 10.3109/03630269.2010.484766.

Abstract

Liver resections are frequently associated with significant ischemia-reperfusion (I-R) injury of the liver remnant. The aim of this study was to investigate whether deferoxamine (DFO) can ameliorate I-R injury during major hepatectomies performed under vascular exclusion of the liver in a porcine model. Twelve female domestic pigs were divided into control (n = 6) and DFO treatment (n = 6) groups and subjected to 150 min. liver ischemia followed by 70% hepatectomy and 24 hours reperfusion. Pigs in the DFO group received a continuous intravenous infusion of 100 mg/kg DFO. Liver remnant injury was evaluated by liver function tests, hepatic histology as well as serum and liver tissue malondialdehyde (MDA) concentrations. Deferoxamine-treated animals had reduced total bilirubin, gamma-glutamyl transferase and ammonia levels as well as hepatocyte necrosis and oxidative injury. In a subsequent randomized clinical trial using DFO for I-R protection during major liver surgery, preliminary results revealed amelioration of hepatocellular damage, oxidative and inflammatory serum markers and apoptotic response in liver remnant biopsies.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Deferoxamine / administration & dosage
  • Deferoxamine / therapeutic use*
  • Disease Models, Animal
  • Female
  • Humans
  • Iron Chelating Agents / administration & dosage
  • Iron Chelating Agents / therapeutic use*
  • Liver / injuries*
  • Liver / metabolism
  • Liver / surgery
  • Liver Function Tests
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / surgery
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / surgery
  • Swine

Substances

  • Iron Chelating Agents
  • Deferoxamine